T. Rowe Price Associates’s West Pharmaceutical WST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $132M | Buy |
526,383
+187,116
| +55% | +$46.6M | 0.02% | 553 |
|
|
2025
Q4 | $93.3M | Buy |
339,267
+224,722
| +196% | +$61.5M | 0.01% | 641 |
|
|
2025
Q3 | $30.1M | Sell |
114,545
-3,084
| -3% | -$750K | ﹤0.01% | 952 |
|
|
2025
Q2 | $25.7M | Sell |
117,629
-37,122
| -24% | -$7.94M | ﹤0.01% | 897 |
|
|
2025
Q1 | $34.6M | Sell |
154,751
-370,568
| -71% | -$102M | ﹤0.01% | 823 |
|
|
2024
Q4 | $172M | Sell |
525,319
-736,159
| -58% | -$232M | 0.02% | 457 |
|
|
2024
Q3 | $379M | Sell |
1,261,478
-432,349
| -26% | -$132M | 0.04% | 320 |
|
|
2024
Q2 | $558M | Sell |
1,693,827
-339,063
| -17% | -$120M | 0.07% | 252 |
|
|
2024
Q1 | $804M | Sell |
2,032,890
-294,504
| -13% | -$109M | 0.1% | 192 |
|
|
2023
Q4 | $820M | Sell |
2,327,394
-179,742
| -7% | -$63.6M | 0.11% | 182 |
|
|
2023
Q3 | $941M | Sell |
2,507,136
-330,808
| -12% | -$128M | 0.14% | 153 |
|
|
2023
Q2 | $1.09B | Sell |
2,837,944
-4,757
| -0.2% | -$1.7M | 0.15% | 144 |
|
|
2023
Q1 | $985M | Buy |
2,842,701
+541,540
| +24% | +$158M | 0.15% | 152 |
|
|
2022
Q4 | $542M | Sell |
2,301,161
-1,568,961
| -41% | -$372M | 0.09% | 215 |
|
|
2022
Q3 | $952M | Sell |
3,870,122
-2,377,451
| -38% | -$724M | 0.16% | 135 |
|
|
2022
Q2 | $1.89B | Sell |
6,247,573
-133,485
| -2% | -$43.4M | 0.24% | 88 |
|
|
2022
Q1 | $2.62B | Buy |
6,381,058
+139,157
| +2% | +$54.5M | 0.26% | 75 |
|
|
2021
Q4 | $2.93B | Buy |
6,241,901
+1,151,427
| +23% | +$496M | 0.26% | 79 |
|
|
2021
Q3 | $2.16B | Sell |
5,090,474
-247,898
| -5% | -$105M | 0.2% | 106 |
|
|
2021
Q2 | $1.92B | Buy |
5,338,372
+325,327
| +6% | +$107M | 0.18% | 121 |
|
|
2021
Q1 | $1.41B | Buy |
5,013,045
+388,798
| +8% | +$111M | 0.14% | 165 |
|
|
2020
Q4 | $1.31B | Buy |
4,624,247
+175,527
| +4% | +$49.3M | 0.13% | 166 |
|
|
2020
Q3 | $1.22B | Sell |
4,448,720
-842,293
| -16% | -$223M | 0.14% | 156 |
|
|
2020
Q2 | $1.2B | Sell |
5,291,013
-28,271
| -0.5% | -$5.55M | 0.15% | 145 |
|
|
2020
Q1 | $810M | Sell |
5,319,284
-1,511,705
| -22% | -$233M | 0.13% | 168 |
|
|
2019
Q4 | $1.03B | Sell |
6,830,989
-1,914,982
| -22% | -$279M | 0.13% | 167 |
|
|
2019
Q3 | $1.24B | Sell |
8,745,971
-154,807
| -2% | -$21.3M | 0.18% | 133 |
|
|
2019
Q2 | $1.11B | Buy |
8,900,778
+130,672
| +1% | +$15.4M | 0.16% | 142 |
|
|
2019
Q1 | $966M | Sell |
8,770,106
-224,857
| -2% | -$23.4M | 0.14% | 155 |
|
|
2018
Q4 | $882M | Buy |
8,994,963
+57,859
| +0.6% | +$6.28M | 0.15% | 143 |
|
|
2018
Q3 | $1.1B | Sell |
8,937,104
-697,773
| -7% | -$78.3M | 0.16% | 142 |
|
|
2018
Q2 | $957M | Sell |
9,634,877
-71,736
| -0.7% | -$6.6M | 0.15% | 153 |
|
|
2018
Q1 | $857M | Buy |
9,706,613
+397,166
| +4% | +$37.2M | 0.14% | 172 |
|
|
2017
Q4 | $919M | Sell |
9,309,447
-81,042
| -0.9% | -$7.95M | 0.15% | 150 |
|
|
2017
Q3 | $904M | Buy |
9,390,489
+104,136
| +1% | +$9.42M | 0.15% | 147 |
|
|
2017
Q2 | $878M | Sell |
9,286,353
-6,009
| -0.1% | -$553K | 0.16% | 148 |
|
|
2017
Q1 | $758M | Sell |
9,292,362
-515,827
| -5% | -$43.1M | 0.14% | 166 |
|
|
2016
Q4 | $832M | Buy |
9,808,189
+436,134
| +5% | +$34.3M | 0.17% | 149 |
|
|
2016
Q3 | $698M | Buy |
9,372,055
+411,086
| +5% | +$32.6M | 0.14% | 172 |
|
|
2016
Q2 | $680M | Sell |
8,960,969
-7,301
| -0.1% | -$531K | 0.14% | 170 |
|
|
2016
Q1 | $622M | Buy |
8,968,270
+387,100
| +5% | +$23.3M | 0.13% | 180 |
|
|
2015
Q4 | $517M | Buy |
8,581,170
+646,415
| +8% | +$38.9M | 0.11% | 204 |
|
|
2015
Q3 | $429M | Buy |
7,934,755
+1,424,259
| +22% | +$83M | 0.1% | 236 |
|
|
2015
Q2 | $378M | Buy |
6,510,496
+1,377,986
| +27% | +$76.9M | 0.08% | 286 |
|
|
2015
Q1 | $309M | Buy |
5,132,510
+3,201,841
| +166% | +$171M | 0.06% | 344 |
|
|
2014
Q4 | $103M | Sell |
1,930,669
-38,722
| -2% | -$1.94M | 0.02% | 613 |
|
|
2014
Q3 | $88.2M | Sell |
1,969,391
-24,296
| -1% | -$1.03M | 0.02% | 638 |
|
|
2014
Q2 | $84.1M | Buy |
1,993,687
+10,732
| +0.5% | +$460K | 0.02% | 686 |
|
|
2014
Q1 | $87.3M | Sell |
1,982,955
-6,085
| -0.3% | -$286K | 0.02% | 673 |
|
|
2013
Q4 | $97.6M | Buy |
1,989,040
+39,900
| +2% | +$1.87M | 0.02% | 625 |
|
|
2013
Q3 | $80.2M | Buy |
1,949,140
+148,600
| +8% | +$5.67M | 0.02% | 652 |
|
|
2013
Q2 | $63.3M | Buy |
+1,800,540
| New | +$59.3M | 0.02% | 709 |
|
Other funds holding WST
VCM
VPM
GIM
T. Rowe Price Associates's WST Position: Q1 2026 in Review
T. Rowe Price Associates increased its West Pharmaceutical (WST) stake by 55% in Q1 2026, buying an estimated $46.6M and bringing the position to 526,383 shares worth $132M. The position accounts for 0.02% of the portfolio, ranked #553.
T. Rowe Price Associates first reported a position in WST in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.93B in Q4 2021. 753 funds tracked by Wall St. Rank hold WST as of Q1 2026.
- T. Rowe Price Associates held 526,383 shares of West Pharmaceutical worth $132M as of Q1 2026.
- T. Rowe Price Associates bought 187,116 West Pharmaceutical shares in Q1 2026, an estimated $46.6M.
- West Pharmaceutical made up 0.02% of T. Rowe Price Associates's portfolio in Q1 2026, its #553 holding.
- T. Rowe Price Associates first reported a position in West Pharmaceutical in Q2 2013 and has held it in 52 quarters since.
- T. Rowe Price Associates's West Pharmaceutical position peaked at $2.93B in Q4 2021.
- 753 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.